

SPEAKER PELOSI'S SOCIALIST DRUG PRICING SCHEME MEANS FEWER CURES

Speaker Pelosi's radical socialist drug pricing scheme will lead to **less innovation, fewer cures, and no hope**. It will also make America more reliant on Chinese medical manufacturing, which proved to be a major Achilles' heel during the pandemic.

WHAT EXPERTS ARE SAYING ABOUT H.R. 3:

- "Could lead to as many as 100 fewer drugs entering the United States market over the next decade, or about one-third of the total number of drugs expected to enter the market during that time." ([Trump Administration White House Council of Economic Advisers](#))
- "Reduce[s] by 88% the number of drugs brought to market by small and emerging companies in California alone." ([California Life Sciences Association](#))
- Would raise prices on seniors or limit their access to prescription drugs. ([CBO](#))
- Would devalue the lives of and discriminate against people with disabilities and those with chronic illnesses and preexisting conditions. ([National Council on Disability](#))

FEWER CURES AND TREATMENTS

For families like Khrystal Davis and her son Hunter, we **MUST** stop Speaker Pelosi's socialist drug pricing scheme. Hunter was born with Spinal Muscular Atrophy (SMA), a rare disease that affects the central nervous system. He is alive today because of a breakthrough treatment.



In Khrystal's own words about what H.R. 3 would mean for the rare disease community:

“

“We hold bake sales, runs, parties, and pretty much anything we can think of to raise funds to get research started. The thing is our funds only get researchers so far. Without follow-on funding from the NIH, biotech companies, or biopharmaceutical companies, the research stalls.

“**Research would stall under the price controls tied to reference pricing under H.R. 3.** We know it will, because we don't see clinical trials taking place in or approvals coming from those countries. They are innovation deserts. Just as deserts are a cruel place when you need water to survive, innovation deserts are relentless when you need access to a rare disease treatment to save your child.”

”

H.R. 19 LOWER COSTS MORE CURES ACT

The American people are eager for a modernized health care system, increased choice and transparency, and lower costs. Republicans are leading with a bipartisan bill, the Lower Costs, Mores Cures Act, to protect American's health with effective cures, treatments, and therapies.

H.R. 19, The Lower Costs, More Cures Act:

- Leads to lifesaving new cures and innovation, promotes more low-cost options for patients who need them, and stops drug companies from gaming the system.
- Doesn't make America more reliant on China.
- Provides first-ever out-of-pocket cap for seniors in the Medicare Part D program.
- Caps the cost of insulin for seniors in the Medicare Part D program.
- Empowers patients with more drug price transparency and removes uncertainty at the pharmacy counter.
- Cuts the cost of cancer treatment and other drug administration for Medicare beneficiaries by as much as half.
- Enables strong, pro-America trade agreements to end American subsidizing of other developed countries' health care.
- Includes bipartisan provisions, unlike Speaker Pelosi's partisan and radical drug pricing scheme.

Important to know: H.R. 19 is a bipartisan solution and is ready to become law as soon as possible. All provisions included in H.R. 19 from the 116th Congress had bipartisan cosponsors. 19 provisions signed into law to date. Zero provisions from Speaker Pelosi's partisan and radical drug pricing scheme have been signed into law.

